Impact of Age on Long-Term Clinical Outcomes Following HeartMate 3 LVAD Implantation: Insights From the MOMENTUM 3 Trial.
JACC Heart FailJun 30, 2026 (epub)
Boaz Elad, Jayant K Raikhelkar, Kevin J Clerkin et al.
✦ AI-curated · Sources linked
In 30 seconds
This study analyzed the impact of age on long-term outcomes following HeartMate 3 LVAD implantation using data from the MOMENTUM 3 trial. It included 2,200 patients stratified by age groups. Results indicated that 2-year survival rates decreased significantly with age, with rates of 72.8% in patients aged ≥70 years compared to 89.1% in those <50 years.
Key findings
- 2-year survival rates were 72.8% for patients aged ≥70 years compared to 89.1% for those <50 years.
- Survival free of disabling stroke or reoperation was 70.5% in the ≥70 years group versus 82.3% in the <50 years group.
- Gastrointestinal bleeding events were significantly higher in the ≥70 years group at 0.42 events per patient-year.
Why it matters
Understanding the relationship between age and outcomes in LVAD patients can help clinicians tailor treatment strategies and improve patient selection for advanced heart therapies.